Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression in mesangial cells by restoring angiotensin-converting enzyme 2 level

Hormone and Metabolic Research

Volumn 46, Issue 6, 2014, Pages 379-383

  Ishibashi, Y ^a   Matsui, T ^a   Yamagishi, S ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE 2; AGEs; Ang (1 7); mas receptor

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; AZILSARTAN; MESSENGER RNA; OLMESARTAN; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; PEPTIDE FRAGMENT; TETRAZOLE DERIVATIVE;

ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESANGIUM CELL; PRIORITY JOURNAL; UPREGULATION; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANGIOTENSIN I; CELL LINE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMIDAZOLES; MESANGIAL CELLS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, IMMUNOLOGIC; SUPEROXIDES; TETRAZOLES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84901980075     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0033-1361114     Document Type: Article

References (38)

1. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des: 2005; 11 2279 2299 (Pubitemid 40872698)
2. Yamagishi S., Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharmacol Res: 2011; 64 187 194
3. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med: 2002; 346 1145 1151 (Pubitemid 34984606)
4. Najafian B., Alpers C. E., Fogo A. B. Pathology of human diabetic nephropathy. Contrib Nephrol: 2011; 170 36 47
5. Stieger N., Worthmann K., Schiffer M. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab Res Rev: 2011; 27 207 215
6. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys: 2007; 48 147 157 (Pubitemid 47340881)
7. Stitt A. W., Bucala R., Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci: 1997; 811 115 127
8. D'Agati V., Yan S. F., Ramasamy R., Schmidt A. M. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab: 2010; 21 50 56
9. Yamamoto Y., Kato I., Doi T., Yonekura H., Ohashi S., Takeuchi M., Watanabe T., Yamagishi S., Sakurai S., Takasawa S., Okamoto H., Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest: 2001; 108 261 268 (Pubitemid 32656250)
10. Wendt T. M., Tanji N., Guo J., Kislinger T. R., Qu W., Lu Y., Bucciarelli L. G., Rong L. L., Moser B., Markowitz G. S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P. P., Stern D. M., D'Agati V. D., Schmidt A. M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol: 2003; 162 1123 1137 (Pubitemid 36350658)
11. Cravedi P., Ruggenenti P., Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep: 2005; 9 430 436
12. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets: 2007; 8 952 959
13. Soldatos G., Cooper M. E. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract: 2008; 82 S75 S79
14. Abuissa H., O'Keefe J. Jr. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab: 2008; 10 1157 1166
15. Matsui T., Nishino Y., Maeda S., Takeuchi M., Yamagishi S. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc Res: 2011; 81 269 273
16. Fukami K., Yamagishi S., Kaifu K., Matsui T., Kaida Y., Ueda S., Takeuchi M., Asanuma K., Okuda S. Telmisartan inhibits AGE-induced podocyte damage and detachment. Microvasc Res: 2013; 88 79 83
17. Dilauro M., Burns K. D. Angiotensin-(1-7) and its effects in the kidney. Sci World J: 2009; 9 522 535
18. Agata J., Ura N., Yoshida H., Shinshi Y., Sasaki H., Hyakkoku M., Taniguchi S., Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res: 2006; 29 865 874 (Pubitemid 46062117)
19. Liu C. X., Hu Q., Wang Y., Zhang W., Ma Z. Y., Feng J. B., Wang R., Wang X. P., Dong B., Gao F., Zhang M. X., Zhang Y. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med: 2010; 1-2 59 69
20. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem: 2006; 281 20213 20220 (Pubitemid 44065796)
21. Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi Y., Nakano N., Ikeda H., Yamagishi S., Kitamoto T., Saito T., Makita Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett: 2002; 326 117 120 (Pubitemid 34607573)
22. Ide Y., Matsui T., Ishibashi Y., Takeuchi M., Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res: 2010; 80 227 232
23. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., Motomiya Y., Bucala R., Iida S., Tamaki K., Imaizumi T., Cooper M. E., Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int: 2004; 66 2137 2147 (Pubitemid 41115277)
24. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., Okuda S., Imaizumi T. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res: 2008; 40 10 15 (Pubitemid 350308297)
25. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., Fukami K., Okuda S., Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res: 2008; 75 130 134 (Pubitemid 350266734)
26. Yamagishi S., Takeuchi M., Inoue H. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats. Drugs Exp Clin Res: 2005; 31 45 51 (Pubitemid 350056455)
27. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H., Ishikawa N., Nangaku M., Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol: 2002; 13 2478 2487
28. Mire D. E., Silfani T. N., Pugsley M. K. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol: 2005; 46 585 593 (Pubitemid 41527750)
29. Fujita M., Okuda H., Tsukamoto O., Asano Y., Hirata Y. L., Kim J., Miyatsuka T., Takashima S., Minamino T., Tomoike H., Kitakaze M. Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol: 2006; 26 e138 e142 (Pubitemid 44465705)
30. Iwai M., Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res: 2009; 32 533 536
31. Ferrario C. M., Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol: 2010; 298 F1297 F1305
32. Rabelo L. A., Alenina N., Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res: 2011; 34 154 160
33. Passos-Silva D. G., Verano-Braga T., Santos R. A. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond): 2013; 124 443 456
34. Ichikawa S., Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hyperten Res: 2001; 24 641 646 (Pubitemid 33133777)
35. Haller H., Ito S., Izzo J. L. Jr, Januszewicz A., Katayama S., Menne J., Mimran A., Rabelink T. J., Ritz E., Ruilope L. M., Rump L. C., Viberti G. ROADMAP Trial Investigators Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med: 2010; 364 907 917
36. Takeuchi M., Makita Z., Yanagisawa K., Kameda K., Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med: 1999; 5 393 405 (Pubitemid 29382313)
37. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia: 2006; 49 3094 3099 (Pubitemid 44730314)
38. Schwocho L. R., Masonson H. N. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol: 2001; 41 515 527 (Pubitemid 32381869)